Alexios Matikas

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Var god se min sida på engelska: Alexios Matikas | Karolinska Institutet (ki.se)

Artiklar

Article: ESMO OPEN. 2024;9(10):103714
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.
Agostinetto E; Bruzzone M; Hamy A-S; Kim HJ; Chiodi C; Bernstein-Molho R; Linn S; Pogoda K; Carrasco E; Derouane F; Bajpai J; Nader-Marta G; Lopetegui-Lia N; Partridge AH; Cortesi L; Rousset-Jablonski C; Giugliano F; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Ruddy KJ; Dieci MV; Matikas A; Rozenblit M; Aguilar Y Mendez D; De Marchis L; Borea R; Puglisi F; Pistelli M; Kufel-Grabowska J; Di Rocco R; Mariamidze E; Atzori F; Kourie HR; Popovic L; de Azambuja E; Blondeaux E; Lambertini M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(26):3077-3082
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial
Matikas A; Moebus V; Greil R; Andersson A; Steger GG; Untch M; Fornander T; Malmstroem P; Schmatloch S; Johansson H; Hellstroem M; Brandberg Y; Gnant M; Loibl S; Foukakis T; Bergh J
Article: BRITISH JOURNAL OF CANCER. 2024;131(4):718-728
A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression
Boman C; Liu X; Eriksson Bergman L; Sun W; Tranchell C; Toli MA; Acs B; Bergh J; Foukakis T; Matikas A
Article: ANNALS OF ONCOLOGY. 2024;35(9):792-804
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
Arecco L; Bruzzone M; Bas R; Kim HJ; Di Meglio A; Bernstein-Molho R; Hilbers FS; Pogoda K; Carrasco E; Punie K; Bajpai J; Agostinetto E; Lopetegui-Lia N; Partridge AH; Phillips KA; Toss A; Rousset-Jablonski C; Curigliano G; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Couch FJ; Dieci MV; Matikas A; Rozenblit M; Mendez DA-Y; De Marchis L; Puglisi F; Fabi A; Graff SL; Witzel I; Hernandez AR; Fontana A; Pesce R; Duchnowska R; Pais HL; Sini V; Sokolovic E; de Azambuja E; Ceppi M; Blondeauxt E; Lambertini M
Journal article: ANNALS OF ONCOLOGY. 2024;35:s356
339TiP A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)
Foukakis T; Naume B; Karakatsanis A; Andersson A; Barnekow E; Kessler LE; Einbeigi Z; Engebraten O; Killander F; Linderholm BK; Schiza A; Valachis A; Bergh J; Villacampa G; Zouzos A; Hellström M; Hartman J; Matikas A
Journal article: ANNALS OF ONCOLOGY. 2024;35:s1112
1908P Grading the evidence for physical activity and all outcomes in cancer survivors: An umbrella review of more than 700 meta-analytic associations
Filis P; Markozannes G; Chan D; Mauri D; Foukakis T; Matikas A; Droufakou S; Pentheroudakis G; Tsilidis K
Article: CANCER. 2024;130(16):2746-2762
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study
Schettini F; Blondeaux E; Molinelli C; Bas R; Kim HJ; Di Meglio A; Bernstein Molho R; Linn SC; Pogoda K; Carrasco E; Punie K; Agostinetto E; Lopetegui-Lia N; Phillips K-A; Toss A; Rousset-Jablonski C; Acheritogaray M; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Dieci MV; Matikas A; Rozenblit M; Villarreal-Garza C; De Marchis L; Puglisi F; Vasconcelos de Matos L; Marino M; Teixeira L; Graffeo R; Rognone A; Chirco A; Antone N; Abdou Y; Marhold M; Bozovic-Spasojevic I; Cortes Salgado A; Carmisciano L; Bruzzone M; Curigliano G; Prat A; Lambertini M
Article: SCIENTIFIC REPORTS. 2024;14(1):18275
Systematic review and feasibility study on pre-analytical factors and genomic analyses on archival formalin-fixed paraffin-embedded breast cancer tissue
Salgkamis D; Sifakis EG; Agartz S; Wirta V; Hartman J; Bergh J; Foukakis T; Matikas A; Zerdes I
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(16_suppl):521
Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial.
Matikas A; Gnant M; Johansson H; Untch M; Tsiknakis N; Greil R; Loibl S; Foukakis T; Bergh JCS
Article: NATURE COMMUNICATIONS. 2024;15(1):3837
Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
Wang K; Zerdes I; Johansson HJ; Sarhan D; Sun Y; Kanellis DC; Sifakis EG; Mezheyeuski A; Liu X; Loman N; Hedenfalk I; Bergh J; Bartek J; Hatschek T; Lehtio J; Matikas A; Foukakis T
Journal article: CANCER RESEARCH. 2024;84(9):po1-02-14-po1-02-14
Breast cancer in older women - long-term prognosis by age and subtype in a large population-based cohort
Chiorescu A; Johansson ALV; Valachis A; Matikas A; Frisell J; Holmberg L; Fredriksson I
Journal article: CANCER RESEARCH. 2024;84(9):gs02-13-gs02-13
Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study
Lambertini M; Blondeaux E; Agostinetto E; Hamy-Petit A-S; Kim HJ; Chiodi C; Bernstein-Molho R; Hilbers F; Pogoda K; Lopez EC; Punie K; Bajpai J; Ignatiadis M; Moore H; Phillips K-A; Toss A; Rousset-Jablonski C; Peccatori FA; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong S; Vernieri C; Ruddy K; Dieci MV; Matikas A; Rozenblit M; Garza CV; De Marchis L; Del Mastro L; Puglisi F; Estevez-Diz MDP; Rodriguez-Wallberg KA; Mrinakova B; Meister S; Livraghi L; Clatot F; Yerushalmi R; De Angelis C; Sanchez-Bayona R; Meattini I; Cichowska-Cwalinska N; Berliere M; Salama M; De Giorgi U; Sonnenblick A; Azim H; Partridge A
Journal article: ESMO OPEN. 2024;9:103116
129P Adherence to adjuvant endocrine therapy in the era of combination treatments: A population-based study
Bergman LE; Matikas A; Liu X; Foukakis T
Journal article: ESMO OPEN. 2024;9:103099
111MO Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: Efficacy outcomes and key subgroups after 10 years of follow-up in the randomized phase III PANTHER trial
Foukakis T; Matikas A; Möbus V; Greil R; Andersson A; Steger GG; Untch M; Fornander T; Malmstrom P; Johansson H; Hellström M; Brandberg Y; Gnant MI; Loibl S; Bergh J
Journal article: ESMO OPEN. 2024;9:103131
144P Factors affecting long term outcomes in patients with pathologic complete response after neoadjuvant chemotherapy for early breast cancer: A population-based study
Boman CE; Tranchell C; Liu X; Bergman LE; Toli MA; Bergh J; Foukakis T; Matikas A
Journal article: ESMO OPEN. 2024;9:103074
68P Application of a machine learning model for identifying an ultra-low risk group of early breast cancer patients
Sarafidis M; Sifakis EG; Bergh J; Foukakis T; Matikas A
Article: EUROPEAN JOURNAL OF CANCER. 2024;202:114010
Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors
Helgadottir H; Matikas A; Fernebro J; Frodin J-E; Ekman S; Rodriguez-Wallberg KA
Journal article: ESMO OPEN. 2024;9:103124
137P Adherence to and optimization of guidelines for risk of recurrence/Prosigna testing using a machine learning model: A Swedish multicenter study
Kjällquist U; Tsiknakis N; Acs B; Margolin S; Ekholm M; Kessler LE; Lundgren C; Garcia SG; Olsson EJ; Lindman H; Valachis A; Hartman J; Foukakis T; Matikas A
Article: BREAST CANCER RESEARCH AND TREATMENT. 2024;204(2):299-308
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
Zhu Y; Zerdes I; Matikas A; Cruz IR; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Wang K; Bergh JCS; Hatschek T; Foukakis T
Article: BREAST CANCER RESEARCH. 2024;26(1):38
Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients
Castresana-Aguirre M; Johansson A; Matikas A; Foukakis T; Lindstroem LS; Tobin NP
Article: BREAST CANCER RESEARCH AND TREATMENT. 2024;204(1):79-87
Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study
Digkas E; Smith DR; Wennstig A-K; Matikas A; Tegnelius E; Valachis A
Article: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA). 2024;331(1):49-59
Pregnancy After Breast Cancer in Young BRCA Carriers
Lambertini M; Blondeaux E; Agostinetto E; Hamy A-S; Kim HJ; Di Meglio A; Molho RB; Hilbers F; Pogoda K; Carrasco E; Punie K; Bajpai J; Ignatiadis M; Moore HCF; Phillips K-A; Toss A; Rousset-Jablonski C; Peccatori FA; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Ruddy KJ; Dieci MV; Matikas A; Rozenblit M; Villarreal-Garza C; De Marchis L; Del Mastro L; Puglisi F; Estevez-Diz MDP; Rodriguez-Wallberg KA; Mrinakova B; Meister S; Livraghi L; Clatot F; Yerushalmi R; De Angelis C; Sanchez-Bayona R; Meattini I; Cichowska-Cwalinska N; Berliere M; Salama M; De Giorgi U; Sonnenblick A; Chiodi C; Lee Y-J; Maria C; Azim HAJ; Boni L; Partridge AH
Article: CLINICAL CANCER RESEARCH. 2023;29(3):532-540
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Gryback P; Bjohle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Article: ONCOLOGY RESEARCH AND TREATMENT. 2023;46(3):67-71
Career and Professional Development for Young Oncologists
Mair MJ; Cardone C; Connolly L; Kfoury M; Lambertini M; Lim J; Mariamidze E; Matikas A; Pihlak R; Punie K; Oing C; Sanchez-Bayona R; Sobczuk P; Zhu H; Berghoff AS; Amaral T
Journal article: ANNALS OF ONCOLOGY. 2022;33:s604-s605
143P Efficacy and safety of anthracyclines in neoadjuvant therapy in HER2+ breast cancer. A systematic review and network meta-analysis (NMA)
Javierre GV; Pascual T; Matikas A; Papakonstantinou A
Article: BREAST CANCER RESEARCH AND TREATMENT. 2022;194(1):49-56
Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
Boman C; Kessler LE; Bergh J; Matikas A; Foukakis T
Article: BREAST CARE. 2022;17(3):264-271
Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period
Matikas A; Kotsakis A; Perraki M; Hatzidaki D; Kalbakis K; Kontopodis E; Nikolaou M; Georgoulias V
Article: BRITISH JOURNAL OF CANCER. 2022;126(11):1563-1569
Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer
Matikas A; Kotsakis A; Apostolaki S; Politaki H; Perraki M; Kalbakis K; Nikolaou M; Economopoulou P; Hatzidaki D; Georgoulias V
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):tps1118
KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.
Rugo HS; Sohn J; Gilarranz YJ; Gonzalez-Cortijo L; Sonnenblick A; Sabanathan D; Korbenfeld EP; Egle D; Poirier B; Zagouri F; Matikas A; Aksoy S; Demirci U; Ramos-Elias P; Im S-A; Cardoso F; Jia L; Baccan C; Tryfonidis K; Schmid P
Article: CANCERS. 2022;14(11):2615
Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
Kjallquist U; Acs B; Margolin S; Karlsson E; Kessler LE; Hernandez SG; Ekholm M; Lundgren C; Olsson E; Lindman H; Foukakis T; Matikas A; Hartman J
Journal article: CANCER RESEARCH. 2022;82(4):p3-18-03-p3-18-03
Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC)
Wang K; Duinmeijer A; Matikas A; Altena R; Johansson H; Fredholm H; Foukakis T
Article: NPJ BREAST CANCER. 2021;7(1):144
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
Zerdes I; Simonetti M; Matikas A; Harbers L; Acs B; Boyaci C; Zhang N; Salgkamis D; Agartz S; Moreno-Ruiz P; Bai Y; Rimm DL; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Article: CANCERS. 2021;13(18):4655
Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
Zerdes I; Karafousia V; Mezheyeuski A; Stogiannitsi M; Kuiper R; Ruiz PM; Rassidakis G; Bergh J; Hatschek T; Foukakis T; Matikas A
Article: ESMO OPEN. 2021;6(2):100076
bPrognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
Matikas A; Wang K; Lagoudaki E; Acs B; Zerdes I; Hartman J; Azavedo E; Bjohle J; Carlsson L; Einbeigi Z; Hedenfalk I; Hellstrom M; Lekberg T; Loman N; Saracco A; von Wachenfeldt A; Rotstein S; Bergqvist M; Bergh J; Hatschek T; Foukakis T
Article: ESMO OPEN. 2020;5(6):e001032
PD-1 protein and gene expression as prognostic factors in early breast cancer
Matikas A; Zerdes I; Lovrot J; Sifakis E; Richard F; Sotiriou C; Rassidakis G; Bergh J; Valachis A; Foukakis T
Article: ACTA ONCOLOGICA. 2020;59(11):1382-1387
Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience
Kessler LE; Wiklander O; Hamberg E; Bergh J; Foukakis T; Matikas A
Article: BREAST CANCER RESEARCH AND TREATMENT. 2020;181(3):645-651
Chemotherapy use near the end-of-life in patients with metastatic breast cancer
Kessler LE; Sigfridsson J; Hatzidaki D; Bergh J; Foukakis T; Georgoulias V; Matikas A
Article: MOLECULAR ONCOLOGY. 2020;14(5):951-963
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease
Zerdes I; Sifakis EG; Matikas A; Chretien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
Article: CANCER. 2020;126(6):1175-1182
Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial
Papakonstantinou A; Matikas A; Bengtsson NO; Malmstrom P; Hedayati E; Steger G; Untch M; Hubbert L; Johansson H; Hellstrom M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
Article: ACTA ONCOLOGICA. 2020;59(1):75-81
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer
Papakonstantinou A; Hedayati E; Hellstrom M; Johansson H; Gnant M; Steger G; Greil R; Untch M; Moebus V; Loibl S; Foukakis T; Bergh J; Matikas A
Journal article: ANNALS OF ONCOLOGY. 2019;30:v136
373P Administration of chemotherapy for metastatic breast cancer near the end of life: A population registry study
Kessler LE; Sigfridsson J; Bergh J; Foukakis T; Matikas A
Journal article: ANNALS OF ONCOLOGY. 2019;30:v86-v87
258P Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Papakonstantinou A; Matikas A; Hellström M; Johansson H; Steger G; Greil R; Loibl S; Gnant M; Moebus V; Untch M; Foukakis T; Bergh J
Article: TARGETED ONCOLOGY. 2019;14(3):285-293
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer
Matikas A; Souglakos J; Katsaounis P; Kotsakis A; Kouroupakis P; Pantazopoulos N; Kentepozidis N; Nikolaidi A; Messaritakis I; Tzovara I; Hatzidaki D; Prinarakis E; Georgoulias V
Article: ANNALS OF ONCOLOGY. 2019;30(1):109-114
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients
Matikas A; Foukakis T; Moebus V; Greil R; Bengtsson N-O; Steger GG; Untch M; Johansson H; Hellstrom M; Malmstrom P; Gnant M; Loibl S; Bergh J
Article: ONCOIMMUNOLOGY. 2018;7(9):e1466017
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
Matikas A; Lovrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Hatschek T; Erlandsson A; Foukakis T
Article: BRITISH JOURNAL OF CANCER. 2018;118(4):480-488
Immune gene expression and response to chemotherapy in advanced breast cancer
Foukakis T; Lovrot J; Matikas A; Zerdes I; Lorent J; Tobin N; Suzuki C; Brage SE; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Ferno M; Skoog L; Bergh J; Hatschek T
Article: MOLECULAR ONCOLOGY. 2018;12(1):21-32
Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes
Spiliotaki M; Mavroudis D; Kokotsaki M; Vetsika E-K; Stoupis I; Matikas A; Kallergi G; Georgoulias V; Agelaki S
Journal article: ANNALS OF ONCOLOGY. 2017;28:v68
219P Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
Matikas A; Lövrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Erlandsson A; Hatschek T; Foukakis T
Article: TRANSLATIONAL ONCOLOGY. 2017;10(4):693-698
Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer1
Matikas A; Voutsina A; Lagoudaki E; Hatzidaki D; Trypaki M; Stoupis G; Tzardi M; Mavroudis D; Georgoulias V
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:e12036
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 (SBG 2004-1) randomized trial of tailored dose adjuvant chemotherapy for early breast cancer.
Matikas A; Margolin S; Hellstrom M; Johansson H; Bengtsson N-O; Carlsson L; Edlund P; Karlsson P; Lidbrink E; Linderholm BK; Lindman H; Malmstrom P; Villman KK; Foukakis T; Bergh JCS
Journal article: CANCER RESEARCH. 2017;77:p1-01-12-p1-01-12
Prevalence of insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) of patients with early breast cancer and its association with E-cadherin expression and patient survival
Agelaki S; Spiliotaki M; Kokotsaki M; Matikas A; Vetsika E-K; Georgoulias V; Mavroudis D
Article: ANNALS OF ONCOLOGY. 2016;27(10):1873-1878
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V
Article: BRITISH JOURNAL OF CANCER. 2016;115(7):784-788
A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy
Kotsakis A; Matikas A; Koinis F; Kentepozidis N; Varthalitis II; Karavassilis V; Samantas E; Katsaounis P; Dermitzaki EK; Hatzidaki D; Mavroudis D; Georgoulias V
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2016;78(2):369-376
Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)
Matikas A; Kentepozidis N; Ardavanis A; Vaslamatzis M; Polyzos A; Emmanouilides C; Katsaounis P; Koinis F; Xynogalos S; Christopoulou A; Ziras N; Tegos T; Prinarakis E; Hatzidaki D; Georgoulias V; Kotsakis A
Journal article: FORUM OF CLINICAL ONCOLOGY. 2016;7(1):17-27
Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
Matikas A; Aggelaki S
Article: BREAST CANCER RESEARCH. 2015;17(1):113
Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
Kallergi G; Agelaki S; Papadaki MA; Nasias D; Matikas A; Mavroudis D; Georgoulias V
Article: BMC CANCER. 2015;15:399
Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer
Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
Article: CASE REPORTS IN ONCOLOGICAL MEDICINE. 2015;2015:659624-4
Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI.
Nikolaou C; Matikas A; Papavasilopoulou M; Mavroudis D; Vamvakas L
Journal article: FORUM OF CLINICAL ONCOLOGY. 2014;5(2):20-31
Triple-Negative Breast Cancer: One Or More Entities?
Matikas A; Lazaridis G; Agelaki S
Journal article: JOURNAL OF GERIATRIC ONCOLOGY. 2014;5:s36-s37
Gemcitabine combined with carboplatin in the first-line of treatment of elderly patients with non-small-cell lung cancer: A multicenter phase II trial by the Hellenic Oncology Research Group (HORG)
Karampeazis A; Vamvakas L; Kentepozidis N; Agelaki S; Kotsakis A; Polyzos A; Milaki G; Christophyllakis C; Matikas A; Kouroussis C; Mavroudis D; Georgoulias V
Article: ANTICANCER RESEARCH. 2014;34(9):5111-5115
Plasmablastic Lymphoma of the Breast in an Immunocompetent Patient: Long-lasting Complete Response Induced by Chemotherapy and Autologous Stem Cell Trasplantation
Matikas A; Kanellis G; Papadimitriou C; Papadaki T; Kotsakis A; Dimopoulos MA; Georgoulias V
Article: ANTICANCER RESEARCH. 2014;34(8):4411-4414
A Case of Herpes Simplex-associated Encephalitis After Brain Irradiation for Lung Cancer Metastases
Matikas A; Kontopodis E; Nintos G; Bilidas T; Kofteridis DP; Papadaki EZ; Lyraraki E; Kanatsouli K; Mavroudis D
Article: BMC CANCER. 2014;14:277
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged > 70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
Vamvakas L; Matikas A; Karampeazis A; Hatzidaki D; Kakolyris S; Christophylakis C; Boukovinas I; Polyzos A; Georgoulias V; Souglakos J
Article: CHROMATOGRAPHIA. 2014;77(19-20):1275-1281
Pre-Column Derivatization HPLC Procedure for the Quantitation of Aluminium Chlorohydrate in Antiperspirant Creams Using Quercetin as Chromogenic Reagent
Kalogria E; Varvaresou A; Papageorgiou S; Protopapa E; Tsaknis I; Matikas A; Panderi I
Journal article: JOURNAL OF GERIATRIC ONCOLOGY. 2013;4:s40-s41
A retrospective analysis regarding the parameters, which influence the administration of adjuvant chemotherapy in for elderly patients (>70years) with stage II or III colon cancer in the daily clinical practice
Asimakopoulou N; Papakonstantinou P; Souglakos J; Karampeazis A; Saridaki Z; Koinis P; Matikas A; Nikolaou C; Georgoulias V; Vamvakas L
Article: BMJ CASE REPORTS. 2013;2013:bcr2013200502
A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.
Matikas A; Vardakis N; Souglakos J; Georgoulias V
Article: BMJ CASE REPORTS. 2013;2013:bcr2013008834
A case of acute myelogenous leukaemia characterised by the BCR-FGFR1 translocation.
Matikas A; Tzannou I; Oikonomopoulou D; Bakiri M
Article: BMJ CASE REPORTS. 2013;2013:bcr2012008311
Primary abdominal muscle lymphoma.
Matikas A; Oikonomopoulou D; Tzannou I; Bakiri M
Article: ACTA HAEMATOLOGICA. 2013;130(4):291-296
Primary Bone Lymphoma: A Retrospective Analysis of 22 Patients Treated in a Single Tertiary Center
Matikas A; Briasoulis A; Tzannou I; Oikonomopoulou D; Bakiri M; Karmiris T; Harhalakis N
Visa fler

Alla övriga publikationer

Review: JAMA ONCOLOGY. 2024;10(10):1331-1341
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.
Villacampa G; Navarro V; Matikas A; Ribeiro JM; Schettini F; Tolosa P; Martínez-Sáez O; Sánchez-Bayona R; Ferrero-Cafiero JM; Salvador F; Papakonstantinou A; Prat A; Oliveira M; Pascual T
Editorial comment: OBSTETRICAL AND GYNECOLOGICAL SURVEY. 2024;79(8):446-449
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study Editoral Comment
Lambertini M; Blondeaux E; Agostinetto E; Hamy A-S; Kim HJ; Di Meglio A; Molho RB; Hilbers F; Pogoda K; Carrasco E; Punie K; Bajpai J; Ignatiadis M; Moore HCF; Phillips K-A; Toss A; Rousset-Jablonski C; Peccatori FA; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Ruddy KJ; Dieci MV; Matikas A; Rozenblit M; Villarreal-Garza C; de Marchis L; del Mastro L; Puglisi F; Estevez-Diz MDP; Rodriguez-Wallberg KA; Mrinakova B; Meister S; Livraghi L; Clatot F; Yerushalmi R; de Angelis C; Sanchez-Bayona R; Meattini I; Cichowska-Cwalinska N; Berliere M; Salama M; de Giorgi U; Sonnenblick A; Chiodi C; Lee Y-J; Maria C; Azim Jr HA; Boni L; Partridge AH
Conference publication: CANCER RESEARCH. 2024;84(9):po2-07-06-po2-07-06
Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial
Wang K; Zhu Y; Zerdes I; Sifakis E; Manikis G; Salgkamis D; Tsiknakis N; Harbers L; Crosetto N; Bergh J; Matikas A; Hatschek T; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103031
23P Longitudinal evaluation of PAM50 molecular subtypes in patients receiving neoadjuvant HER2-targeted therapy in the PREDIX HER2 trial
Zhu Y; Sifakis EG; Wang K; Zerdes I; Bergh J; Hatschek T; Matikas A; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103110
122P Primary results and biomarker analysis from PREDIX LumB: A prospective randomized phase II trial investigating sequence of neoadjuvant chemotherapy and palbociclib/endocrine therapy for luminal breast cancer
Matikas A; Bjöhle J; Barnekow E; Isakssonfriman E; Zouzos A; Tzoras E; Johansson H; Margolin S; Acs B; Boyaci C; Sun W; Zerdes I; Kessler LE; Grybäck P; Hellström M; Hartman J; Brandberg Y; Bergh J; Hatschek T; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103063
56P Longitudinal circulating plasma protein immune profiling reveals biomarkers of treatment response to neoadjuvant trastuzumab-emtansine (T-DM1) in early HER2-positive breast cancer: A secondary analysis of the phase II PREDIX HER2 trial
Zerdes I; Wang K; Salgkamis D; Zhu Y; Sifakis EG; Acs B; Hartman J; Hatschek T; Bergh J; Matikas A; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103075
69P Deep learning prognostication through prediction of TP53 gene mutation status on breast cancer hematoxylin and eosin slides
Tsiknakis N; Salgkamis D; Tzoras E; Wang K; Liu X; Manikis G; Sifakis EG; Bergh J; Marias K; Zerdes I; Matikas A; Foukakis T
Editorial comment: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 2024;103(4):775-778
Breast cancer during pregnancy-The oncologist's point of view
Matikas A; Bergh J
Preprint: RESEARCH SQUARE. 2024
Adherence to and optimization of guidelines for Risk of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
Kjällquist U; Tsiknakis N; Acs B; Margolin S; Kessler LE; Levy S; Ekholm M; Lundgren C; Olsson E; Lindman H; Valachis A; Hartman J; Foukakis T; Matikas A
Conference publication: EUROPEAN JOURNAL OF CANCER. 2024;200:98-99
Multiomic profiling reveals predictive molecular characteristics of response to neoadjuvant antibody-drug conjugate versus chemotherapy and dual HER2 blockade in HER2 positive breast cancer
Foukakis T; Wang K; Zerdes I; Zhu Y; Sifakis E; Tsiknakis N; Manikis G; Salgkamis D; Harbers L; Bergh J; Johansson H; Crosetto N; Lehtio J; Matikas A; Hatschek T
Review: ONCOLOGIST. 2024;29(1):1-7
Impact of Primary Breast Surgery on Overall Survival of Patients With De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Villacampa G; Papakonstantinou A; Fredriksson I; Matikas A
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(16)
Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial
Matikas A; Gnant M; Johansson H; Untch M; Tsiknakis N; Greil R; Loibl S; Foukakis T; Bergh JCS
Review: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2023;192:104189
The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review
Filis P; Zerdes I; Soumala T; Matikas A; Foukakis T
Editorial comment: ESMO OPEN. 2023;8(5):101625
Young oncologists' perspective on the role and future of the clinician-scientist in oncology
Lim KHJ; Westphalen CB; Berghoff AS; Cardone C; Connolly EA; Guven DC; Kfoury M; Kocakavuk E; Mando P; Mariamidze E; Matikas A; Moutafi M; Oing C; Pihlak R; Punie K; Sanchez-Bayona R; Sobczuk P; Starzer AM; Vuger AT; Zhu H; Cruz-Ordinario MVB; Altuna SC; Canario R; Vuylsteke P; Banerjee S; de Azambuja E; Cervantes A; Lambertini M; Mateo J; Amaral T
Meeting abstract: ANNALS OF ONCOLOGY. 2023;34:s307-s308
Machine learning-based characterization of tumor-immune microenvironment at a spatial and multiplexed resolution in early breast cancer: A sub-study of the EORTC 10994/BIG 1-00 randomized phase III trial with long-term follow-up
Zerdes I; Matikas A; Mezheyeuski A; Acs B; Johansson H; Manikis G; Boyaci C; Boman CE; Poncet C; Ignatiadis M; Bai Y; Rimm D; MacGrogan G; Cameron DA; Bergh J; Bonnefoi H; Foukakis T
Review: EUROPEAN JOURNAL OF CANCER. 2023;190:112885
Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis
Villacampa G; Matikas A; Oliveira M; Prat A; Pascual T; Papakonstantinou A
Preprint: RESEARCH SQUARE. 2023
Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study
Digkas E; Smith D; Wennstig A-K; Matikas A; Tegnelius E; Valachis A
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary File S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary File S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Data from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Editorial comment: MOLECULAR ONCOLOGY. 2023;17(4):545-547
The interplay between eosinophils and T cells in breast cancer immunotherapy
Zerdes I; Matikas A; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Data from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Meeting abstract: CANCER RESEARCH. 2023;83(5):p2-21-02-p2-21-02
Longitudinal tumor-immune microenvironment changes in patients with clinical luminal A early breast cancer treated with neoadjuvant palbociclib and endocrine therapy: results from the Swedish randomized PREDIX Luminal A trial
Zerdes I; Salgkamis D; Matikas A; Selander L; Wang K; Tzoras E; Sifakis E; Agartz S; Chen X; Hellstrom M; Hartman J; Bergh J; Foukakis T; Hatschek T
Meeting abstract: CANCER RESEARCH. 2023;83(5):p5-02-20-p5-02-20
Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial
Wang K; Zhu Y; Zerdes I; Matikas A; Sifakis E; Salgkamis D; Bjohle J; Elinder E; Margolin S; Campos AB; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Johansson H; Hellstrom M; Azavedo E; Hartman J; Bergh J; Hatschek T; Foukakis T
Preprint: MEDRXIV. 2023
Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients
Castresana-Aguirre M; Johansson A; Matikas A; Foukakis T; Lindström L; Tobin N
Book chapter: BREAST CANCER MANAGEMENT FOR SURGEONS. 2023;p. 203-218
Principles of Primary Systemic Therapy
Foukakis T; Matikas A; Valachis A
Book chapter: INTRODUCTION TO ARTIFICIAL INTELLIGENCE: IMAGING INFORMATICS FOR HEALTHCARE PROFESSIONALS. 2023;p. 13-37
Using Commercial and Open-Source Tools for Artificial Intelligence: A Case Demonstration on a Complete Radiomics Pipeline
Stamoulou E; Spanakis C; Nikiforaki K; Karantanas AH; Tsiknakis N; Matikas A; Foukakis T; Manikis GC
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):e12598
Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.
Zhu Y; Wang K; Zerdes I; Matikas A; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Bergh JCS; Hatschek T; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):e12620
Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis.
Zerdes I; Zhu Y; Tzoras E; Matikas A; Bergh JCS; Valachis A; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):593
Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.
Matikas A; Johansson H; Grybäck P; Bjöhle J; Lekberg T; Fredholm H; Acs B; Elinder E; Isaksson-Friman E; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh JCS; Hatschek T; Foukakis T
Letter: BRITISH JOURNAL OF CANCER. 2022;126(11):1661-1662
Response to A. Chauhan and A. Pal
Matikas A; Georgoulias V
Meeting abstract: ANNALS OF ONCOLOGY. 2022;33:S125
Longitudinal proteogenomic profiling reveals therapeutic vulnerabilities of immunometabolism in breast cancer
Wang K; Zerdes I; Sifakis EG; Johansson HJ; Mezheyeuski A; Lehtio J; Bergh J; Hatschek T; Matikas A; Foukakis T
Review: CANCERS. 2022;14(8):1999
Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
Tzoras E; Zerdes I; Tsiknakis N; Manikis GC; Mezheyeuski A; Bergh J; Matikas A; Foukakis T
Conference publication: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. 2022;18:233-234
Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49
Schmid P; Sohn JH; Jerez Gilarranz Y; Gonzalez-Cortijo L; Sonnenblick A; Sabanathan D; Korbenfeld E; Egle D; Poirier B; Zagouri F; Matikas A; Aksoy S; Demirci U; Ramos-Elias P; Im S-A; Cardoso F; Jia L; Hirshfield K; Tryfonidis K; Rugo HS
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)
KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer
Rugo HS; Sohn J; Jerez Gilarranz Y; Gonzalez-Cortijo L; Sonnenblick A; Sabanathan D; Pablo Korbenfeld E; Egle D; Poirier B; Zagouri F; Matikas A; Aksoy S; Demirci U; Ramos-Elias P; Im S-A; Cardoso F; Jia L; Baccan C; Tryfonidis K; Schmid P
Conference publication: ANNALS OF ONCOLOGY. 2022;33(7):S604
Efficacy and safety of anthracyclines in neoadjuvant therapy in HER2+breast cancer. A systematic review and network meta-analysis (NMA)
Villacampa Javierre G; Pascual T; Matikas A; Papakonstantinou A
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)
Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.
Zhu Y; Wang K; Zerdes I; Matikas A; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Bergh JCS; Hatschek T; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)
Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis.
Zerdes I; Zhu Y; Tzoras E; Matikas A; Bergh JCS; Valachis A; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)
Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.
Matikas A; Johansson H; Gryback P; Bjohle J; Lekberg T; Fredholm H; Acs B; Elinder E; Isaksson-Friman E; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh JCS; Hatschek T; Foukakis T
Review: FRONTIERS IN ONCOLOGY. 2022;12:999843
Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis
Zhu Y; Tzoras E; Matikas A; Bergh J; Valachis A; Zerdes I; Foukakis T
Editorial comment: ANNALS OF ONCOLOGY. 2021;32(12):1457-1459
Adjuvant abemaciclib for high-risk breast cancer: the story continues
Spring L; Matikas A; Bardia A; Foukakis T
Review: CANCER TREATMENT REVIEWS. 2021;99:102257
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis
Boman C; Zerdes I; Martensson K; Bergh J; Foukakis T; Valachis A; Matikas A
Editorial comment: BREAST CARE. 2021;16(4):422-428
Expert Discussion: HER2-Positive Breast Cancer
Foukakis T; Matikas A; Oikonomidou O; Andreopoulou E; Mavroudis D
Conference publication: ANNALS OF ONCOLOGY. 2021;32:S70-S71
Women with short survival after diagnosis of metastatic breast cancer: A population-based registry study
Boman CE; Kessler LE; Bergh J; Matikas A; Foukakis T
Conference publication: CANCER RESEARCH. 2021;81(4_Supplement):ps18-27-ps18-27
Abstract PS18-27: Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial
Zerdes I; Simonetti M; Matikas A; Harbers L; Zhang N; Salgkamis D; Agartz S; Zacharouli M; Moreno-Ruiz P; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Editorial comment: ANNALS OF ONCOLOGY. 2021;32(2):129-132
SOLAR1s: alpelisib returns to earth?
Matikas A; Foukakis T
Editorial comment: ESMO OPEN. 2021;6(1):100017
ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
Punie K; Matikas A
Editorial comment: ESMO OPEN. 2021;6(1):100014
ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer
Matikas A; Lambertini M
Conference publication: CANCER RESEARCH. 2021;81(4)
Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial
Zerdes I; Simonetti M; Matikas A; Harbers L; Zhang N; Salgkamis D; Agartz S; Zacharouli M; Moreno-Ruiz P; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Conference publication: ANNALS OF ONCOLOGY. 2020;31:S1196
Disparities in access to oncology clinical trials in Europe in the period 2009-2019
Carneiro A; Amaral TMS; Brandao M; Scheffler M; Bol K; Ferrara R; Jalving M; Lo Russo G; Marquez-Rodas I; Matikas A; Mezquita L; Morgan G; Onesti CE; Pilotto S; Saloustros E; Trapani D
Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S328
Heterogeneity of PD-L1 expression at the protein and mRNA levels in early breast cancer
Zerdes I; Stogiannitsi M; Bergh J; Hatschek T; Foukakis T; Matikas A
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15_suppl):545
PD-1 protein and gene expression in early breast cancer: Prognostic implications.
Zerdes I; Matikas A; Lövrot J; Sifakis EG; Richard F; Sotiriou C; Rassidakis GZ; Bergh JCS; Valachis A; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15)
PD-1 protein and gene expression in early breast cancer: Prognostic implications.
Zerdes I; Matikas A; Lovrot J; Sifakis EG; Richard F; Sotiriou C; Rassidakis GZ; Bergh JCS; Valachis A; Foukakis T
Review: CLINICAL CANCER RESEARCH. 2019;25(18):5717-5726
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data
Matikas A; Zerdes I; Lovrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
Review: ANNALS OF ONCOLOGY. 2019;30(7):1044-1050
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
Matikas A; Foukakis T; Swain S; Bergh J
Review: AUTOIMMUNITY REVIEWS. 2019;18(6):615-620
G-CSF-induced aortitis: Two cases and review of the literature
Parodis I; Dani L; Notarnicola A; Martenhed G; Fernstrom P; Matikas A; Wiklander OPB
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):553
Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.
Foukakis T; Papakonstantinou A; Matikas A; Bengtsson N-O; Malmstrom P; Hedayati E; Steger GG; Untch M; Hubbert L; Johansson H; Hellstrom M; Gnant M; Loibl S; Greil R; Moebus V; Bergh JCS
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):550
Prognostic value of PD-L1 gene expression with Recurrence Score and 70-gene signature in patients with ER+/HER2-early breast cancer.
Zerdes I; Sifakis EG; Tobin N; Bergh JCS; Matikas A; Foukakis T
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):e14284
Prognostic implications of PD-L1 expression in breast cancer at the protein and mRNA levels.
Matikas A; Zerdes I; Lovrot J; Richard F; Sotiriou C; Bergh JCS; Valachis A; Foukakis T
Review: CANCERS. 2019;11(5):E628-628
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chretien S; Zerdes I; Bergh J; Matikas A; Foukakis T
Editorial comment: JOURNAL OF INTERNAL MEDICINE. 2019;285(4):395-397
Minimally invasive tissue access as a tool for delivering personalized medicine - with focus on oncology
Matikas A; Foukakis T; Bergh J
Meeting abstract: CANCER RESEARCH. 2019;79(4):p2-08-25-p2-08-25
PD-L1 expression at the protein and RNA levels as prognostic factor in early breast cancer
Zerdes I; Sifakis E; Matikas A; Tobin NP; Charlotte R; Rassidakis GZ; Bergh J; Foukakis T
Conference publication: ANNALS OF ONCOLOGY. 2019;30:86
Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Papakonstantinou A; Matikas A; Hellstrom M; Johansson H; Steger G; Greil R; Loibl S; Gnant M; Moebus V; Untch M; Foukakis T; Bergh J
Conference publication: ANNALS OF ONCOLOGY. 2019;30
Administration of chemotherapy for metastatic breast cancer near the end of life: A population registry study
Kessler LE; Sigfridsson J; Bergh J; Foukakis T; Matikas A
Letter: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(11):1280-1281
RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Matikas A; Foukakis T; Bergh J
Review: ONCOGENE. 2018;37(34):4639-4661
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):538
Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.
Matikas A; Foukakis T; Moebus V; Greil R; Bengtsson N-O; Steger GG; Untch M; Johansson H; Hellstrom M; Malmstrom P; Gnant M; Loibl S; Bergh JCS
Published conference paper: BREAST CANCER RESEARCH AND TREATMENT. 2018;168(2):349-355
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
Matikas A; Margolin S; Hellstrom M; Johansson H; Bengtsson N-O; Karlsson L; Edlund P; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmstrom P; Villman K; Foukakis T; Bergh J
Review: ACTA ONCOLOGICA. 2017;56(9):1143-1151
Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts
Matikas A; Foukakis T; Bergh J
Review: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2017;114:91-101
Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine
Matikas A; Foukakis T; Bergh J
Review: EXPERT REVIEW OF ANTICANCER THERAPY. 2017;17(4):319-326
Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer
Matikas A; Foukakis T; Michalakis I; Georgoulias V
Review: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2017;110:1-12
Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity
Matikas A; Mistriotis D; Georgoulias V; Kotsakis A
Conference publication: ANNALS OF ONCOLOGY. 2017;28
Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
Matikas A; Lovrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Erlandsson A; Hatschek T; Foukakis T
Review: WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY. 2016;8(12):810-818
Role of circulating free DNA in colorectal cancer
Matikas A; Voutsina A; Trypaki M; Georgoulias V
Review: EXPERT REVIEW OF RESPIRATORY MEDICINE. 2016;10(11):1229-1241
The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update
Matikas A; Georgoulias V; Kotsakis A
Review: CLINICAL LUNG CANCER. 2016;17(6):507-516
Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges
Matikas A; Syrigos KN; Agelaki S
Review: CLINICAL LUNG CANCER. 2016;17(6):474-482
Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer
Matikas A; Kentepozidis N; Georgoulias V; Kotsakis A
Review: TRANSLATIONAL LUNG CANCER RESEARCH. 2016;5(4):389-400
Targeting angiogenesis in small cell lung cancer
Stratigos M; Matikas A; Voutsina A; Mavroudis D; Georgoulias V
Review: EXPERT OPINION ON EMERGING DRUGS. 2016;21(2):157-166
Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients
Matikas A; Georgoulias V; Kotsakis A
Conference publication: CANCER RESEARCH. 2015;75:374
Expression of the autophagosomal marker LC3 on circulating tumor cells (CTCs) of patients with early and metastatic breast cancer (BC)
Spiliotaki M; Koukorava C; Matikas A; Georgoulias V; Mavroudis D; Agelaki S
Review: CLINICAL LUNG CANCER. 2015;16(4):252-261
Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs
Matikas A; Mistriotis D; Georgoulias V; Kotsakis A
Review: CANCERS. 2015;7(1):439-449
The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
Matikas A; Asimakopoulou N; Georgoulias V; Souglakos J
Review: FUTURE ONCOLOGY. 2015;11(6):997-1009
Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma
Matikas A; Mavroudis D
Visa fler

Forskningsbidrag

Matikas, Alexios – Optimization of prognostication and therapy prediction in ER-positive, HER2-negative early breast cancer by leveraging integrated proteogenomic analyses
Swedish Cancer Society
1 January 2023
Randomized Trials on Biology-Driven De-escalation of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE master protocol
Swedish Research Council
1 December 2020 - 31 December 2024

Om mig

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI